Larimar Therapeutics Azioni (NASDAQ: LRMR)

Ultime notizie per Larimar Therapeutics (NASDAQ:LRMR) Azioni

LARIMAR THERAPEUTICS INC

Larimar Therapeutics

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics Inc

Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) has outperformed the market over the past 5 years by 14.32% on an annualized basis producing an average annual return of 28.72%. Currently, Ovintiv has a market capitalization of $10.13 billion. 
Buying $1000 In OVV: If an investor had bought $1000 of OVV stock 5 years ago, it would be worth $3,527.65 today based on a price of $38.91 for OVV at the time of writing.
<h3>Ovintiv's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753134313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

Here's How Much $1000 Invested In Ovintiv 5 Years Ago Would Be Worth Today

Peapack Gladstone Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGC#NASDAQ">PGC</a>) reported quarterly earnings of $0.45 per share which missed the analyst consensus estimate of $0.62 by 27.07 percent. This is a 7.14 percent increase over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $69.741 million which missed the analyst consensus estimate of $69.775 million by 0.05 percent. This is a 23.22 percent increase over sales of $56.597 million the same period last year.

Earnings

Earnings Misses

Peapack Gladstone Finl Q2 2025 GAAP EPS $0.45 Misses $0.62 Estimate, Sales $69.741M Miss $69.775M Estimate

AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&amp;D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide.
The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.
The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production.
The $50 billion investment across our R&amp;D and manufacturing footprint in the US over the next five years also includes:
<ul>
<li>Expansion of our R&amp;D facility in Gaithersburg, Maryland</li>
<li>State-of-the-art R&amp;D center in Kendall Square, Cambridge, Massachusetts</li>
<li>Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California</li>
<li>Continuous manufacturing expansion in Mount Vernon, Indiana</li>
<li>Specialty manufacturing expansion in Coppell, Texas</li>
<li>New sites to supply clinical trials</li>
<li>Our growing research and development investment in novel medicines</li>
</ul>
Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US.
Howard Lutnick, US Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here."
Governor Glenn Youngkin, Commonwealth of Virginia, said: "I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth."
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines."

General

AstraZeneca To Invest $50B In The U.S. By 2030, Building On America's Global Leadership In Medicines Manufacturing And R&D; Investment Will Support AstraZeneca's Ambition To Reach $80B Revenue By 2030, With 50% Generated In The U.S

Agilysys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) reported financial results for the first quarter after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/07/b46531818/agilysys-announces-record-revenue-of-76-7m-in-fiscal-2026-first-quarter">of the report</a>.
<ul class="wp-block-list">
<li>Q1 Revenue: $76.7 million, versus <a href="http://benzinga.com/quote/agys/earnings">estimates</a> of $74.35 million</li>
</ul>
<ul class="wp-block-list">
<li>Q1 Adjusted EPS: 33 cents, versus estimates of 36 cents</li>
</ul>
Total revenue increased 20.7% year-over-year. Recurring revenue totaled $48.6 million and subscription revenue increased 44.3% year-over-year. 
The hospitality software solutions company reported free cash flow of negative $5 million. Agilysys ended the quarter with a cash balance of $55.6 million.
&#8220;We continue to enjoy excellent selling momentum with consistent, robust demand for the modernized state-of-the-art cloud-native ecosystem of hospitality-focused software solutions. Strong sales drove the recurring and services revenue backlog to record levels, despite strong implementation success and record services revenue,&#8221; said Ramesh Srinivasan, president and CEO of Agilysys.
Outlook: Agilysys expects fiscal 2026 revenue to be in the range of $308 million to $312 million versus estimates of $309.99 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company also guided for subscription revenue growth of 27%. 
&#8220;Sales remained strong throughout the quarter, including with respect to point of sale products compared to the prior year. We are continuing to execute at the elevated levels we saw as we exited fiscal year 2025 and are well positioned to achieve our 2026 fiscal year financial plan,&#8221; said Dave Wood, CFO of Agilysys.
AGYS Price Action: <a href="http://benzinga.com/quote/AGYS">Agilysys shares</a> were down 11.07% in after-hours, trading at $104 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46533157/steel-dynamics-stock-sinks-after-q2-results-miss-estimates-details">Steel Dynamics Stock Sinks After Q2 Results Miss Estimates: Details</a></li>
</ul>
Photo: Shutterstock.

Guidance

Movers

AGYS

Agilysys Stock Tumbles On Q1 Earnings

Offerings

Equitable Holdings Files For Mixed Shelf Offering; Size Not Disclosed

Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) stock traded higher on Monday after Morgan Stanley weighed in on the stock. Here&#8217;s what you need to know.
What To Know: Morgan Stanley maintained an Overweight rating on Alphabet and raised its price target from $185 to $205.
The company is set to report second quarter earnings on Wednesday after the market closes.
Analysts estimate earnings per share of $2.17 and revenue of $93.72 billion. Over the past few quarters, the company has beaten both EPS and revenue expectations.
In the first quarter, Alphabet reported earnings of $2.81 per share, topping the consensus estimate of $2.02. Revenue came in at $90.23 billion, beating the $89.20 billion estimate by 1.16% and marking a 12% year-over-year increase.
The company broke down its first-quarter results further, noting a 10% year-over-year increase in Google Services revenue to $77.3 billion, driven by strong performance across Google Search, subscriptions, platforms, and devices. Google Cloud revenue rose 28% to $12.3 billion, led by growth in Google Cloud Platform.
Analyst Changes: Ahead of the earnings report, multiple other analysts have issued price target adjustments.
<ul class="wp-block-list">
<li>UBS analyst Lloyd Walmsley maintained a Neutral rating on Alphabet and raised the price target from&nbsp;$186&nbsp;to&nbsp;$192.</li>
<li>BMO Capital analyst Brian Pitz reiterated an Outperform rating on Alphabet and raised the price target from&nbsp;$200&nbsp;to&nbsp;$208.</li>
</ul>
The consensus price target for Alphabet is $163.07, with the lowest price target at $115 and the highest price target at $235.
How To Buy Alphabet Stock
By now you're likely curious about how to participate in the market for Alphabet &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
See Also: <a href="https://www.benzinga.com/trading-ideas/previews/25/07/46525850/general-motors-q2-preview-ev-strength-could-seal-13th-straight-revenue-beat">General Motors Q2 Preview: EV Strength Could Seal 13th Straight Revenue Beat</a>
GOOG Price Action: At the time of writing, Alphabet stock closed Monday up 2.8% at $191.15, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Image via Shutterstock

GOOG

GOOGL

Alphabet Stock Is Trading Higher Monday: What's Going On?

<a href="https://www.semafor.com/article/07/21/2025/berkshire-bnsf-bankers-railroad-merger">https://www.semafor.com/article/07/21/2025/berkshire-bnsf-bankers-railroad-merger</a>

BRK/A

BRK/B

'Berkshire-owned BNSF taps bankers for its own rail acquisition'- Semafor

RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) reported quarterly earnings of $0.36 per share which met the analyst consensus estimate. This is a 7.69 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $35.812 million which beat the analyst consensus estimate of $29.601 million by 20.98 percent. This is a 30.45 percent increase over sales of $27.453 million the same period last year.

Earnings Beats

UPDATE: RBB Bancorp Q2 Adj. EPS $0.36, Inline, Sales $35.812M Beat $29.601M Estimate

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) has outperformed the market over the past 10 years by 7.59% on an annualized basis producing an average annual return of 19.22%. Currently, Autodesk has a market capitalization of $63.15 billion. 
Buying $100 In ADSK: If an investor had bought $100 of ADSK stock 10 years ago, it would be worth $578.18 today based on a price of $295.16 for ADSK at the time of writing.
<h3>Autodesk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753132512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADSK

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

MSFT

Reuters Cites Google Saying At Least Some Of Microsoft Server Hacks Carried Out By 'China-Nexus Threat Actor

<a href="https://www.wsj.com/tech/ai/softbank-openai-a3dc57b4">https://www.wsj.com/tech/ai/softbank-openai-a3dc57b4</a>

'SoftBank and Open AI's $500 Billion AI Project Struggles to Get Off Ground'- WSJ

Set forth below are preliminary estimates of selected unaudited financial information and other information for the three months ended June 30, 2025, and actual unaudited financial results for the three months ended June 30, 2024. We have provided ranges of certain preliminary results below because our closing procedures for our fiscal quarter ended June 30, 2025 are not yet complete. These ranges are based on the information available to us as of the date of this press release. Our final results remain subject to customary closing procedures or subsequent events, however we do not expect our final results to materially differ from the preliminary results shown below. These preliminary estimates are forward-looking statements. Our unaudited financial results as of the three months ended June 30, 2025 are not yet finalized. During the course of the preparation of our unaudited financial statements and the notes thereto by management, additional items that require adjustments to the preliminary results presented below may be identified.
The preliminary results provided below do not represent a comprehensive statement of our financial results and should not be viewed as a substitute for the financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP). In addition, the preliminary results for the three months ended June 30, 2025 are not necessarily indicative of the results to be achieved in any future period.
&nbsp;
The estimates of Karman&#39;s revenue, gross profit, pretax income, net income, funded backlog and adjusted EBITDA, as of June 30, 2025 are preliminary, have not been audited, do not present all information necessary for an understanding of Karman&#39;s financial condition as of June 30, 2025, and are subject to change upon completion of Karman&#39;s financial statement closing procedures. The preliminary financial data included in the above has been prepared by, and is the responsibility of, Karman&#39;s management. Karman&#39;s independent registered public accounting firm has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, Karman&#39;s independent registered public accounting firm does not express an opinion or any other form of assurance with respect thereto.
For the three months ended June 30, 2025, we expect revenue to be between $114.50 million and $115.00 million, representing an estimated increase of approximately 34.6% and 35.2%, compared to revenue of $85.04 million for the three months ended June 30, 2024.
For the three months ended June 30, 2025, we expect total gross profit to be between $46.70 million and $47.00 million, compared to total gross profit of $34.59 million for the three months ended June 30, 2024
For the three months ended June 30, 2025, we expect income before provision for income taxes to be between $8.31 million and $8.40 million, compared to income before provision for income taxes of $4.92 million for the three months ended June 30, 2024.
For the three months ended June 30, 2025, we expect net income to be between $6.17 million and $6.20 million, compared to net income of $4.60 million for the three months ended June 30, 2024.
For the three months ended June 30, 2025, net income margin is expected to be 5.4%, compared to net income margin of 5.4% for the three months ended June 30, 2024.
For the three months ended June 30, 2025, we expect funded backlog to be between $712.00 million and $715.00 million, representing an estimated increase of approximately 34.8% and 35.4%, compared to funded backlog of $528.01 million for the three months ended June 30, 2024.
For the three months ended June 30, 2025, Adjusted EBITDA is expected to be between $34.85 million and $35.15 million, compared to Adjusted EBITDA of $27.42 million for the three months ended June 30, 2024. For the three months ended June 30, 2025, Adjusted EBITDA margin is expected to be between 30.4% and 30.6%, compared to Adjusted EBITDA margin of 32.2% for the three months ended June 30, 2024.

KRMN

Karman Space & Defense Releases Preliminary Q2 Fiscal Year 2025 Financial Results; Q2 Revenue Expected Between $114.50M-$115.00M, Up 34.6%-35.2% YoY

AutoCanada Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACQ#TSX">ACQ</a>), a multi-location North American automobile dealership group, today announced that it has selected CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>), the fastest-growing automotive shopping site in Canada1, as its preferred partner in Canada. Through this long-term relationship, AutoCanada will have access to the power and reach of CarGurus&#39; leading listings marketplace, advanced digital marketing and retail solutions, and market intelligence powered by proprietary data and predictive insights.
AutoCanada dealers will benefit from CarGurus&#39; solutions that help maximize visibility, connect with ready-to-buy shoppers, and make more data-informed decisions on vehicle pricing, inventory management, and digital advertising. The group&#39;s 64 franchised dealerships and three used car dealerships in Canada will also have ongoing access to strategic consultation from CarGurus&#39; in-person dealer engagement team, helping them navigate shifting market dynamics and consumer behavior.

Global

CARG

CarGurus Named Preferred Partner By AutoCanada To Enhance Digital Strategy Across Dealerships

<h3>Gainers</h3>
<ul>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares moved upwards by 7.5% to $1.29 during Monday's after-market session. The market value of their outstanding shares is at $118.9 million. </li>
<li>Children's Place (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) shares moved upwards by 4.98% to $5.48. The company's market cap stands at $114.1 million. </li>
<li>Kaival Brands Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) shares moved upwards by 4.16% to $0.5. The market value of their outstanding shares is at $5.8 million. </li>
<li>Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) shares rose 4.02% to $1.55. The market value of their outstanding shares is at $20.9 million. </li>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock rose 3.98% to $26.25. The market value of their outstanding shares is at $2.7 billion. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) shares rose 3.33% to $1.86. The company's market cap stands at $17.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lindblad Expeditions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) stock decreased by 8.0% to $11.36 during Monday's after-market session. The company's market cap stands at $681.1 million. </li>
<li>Tuniu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOUR#NASDAQ">TOUR</a>) stock fell 3.79% to $0.84. The company's market cap stands at $99.8 million. </li>
<li>Newton Golf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTG#NASDAQ">NWTG</a>) stock fell 3.66% to $1.58. The market value of their outstanding shares is at $6.7 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares fell 3.4% to $0.68. The company's market cap stands at $34.6 million. </li>
<li>Perfect Moment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#AMEX">PMNT</a>) stock fell 3.34% to $0.35. </li>
<li>Autozi Internet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) shares decreased by 3.32% to $0.26. The company's market cap stands at $29.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRLT

GDHG

KAVL

LIND

NWTG

PLCE

PMNT

SBET

TOUR

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares moved upwards by 48.9% to $460.02 during Monday's after-market session. The market value of their outstanding shares is at $8.9 billion. The company's, Q2 earnings came out today. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock increased by 7.65% to $3.78. The company's market cap stands at $125.7 million. </li>
<li>Rafael Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) stock rose 7.54% to $2.28. The market value of their outstanding shares is at $72.3 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 7.37% to $12.52. The market value of their outstanding shares is at $20.7 million. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) stock rose 7.36% to $0.65. The company's market cap stands at $39.1 million. </li>
<li>Charles River (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRL#NYSE">CRL</a>) shares increased by 6.81% to $160.0. The company's market cap stands at $7.8 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 9.8% to $0.02 during Monday's after-market session. The market value of their outstanding shares is at $7.8 million. </li>
<li>Barinthus Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRNS#NASDAQ">BRNS</a>) shares fell 9.65% to $1.78. The market value of their outstanding shares is at $60.4 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock decreased by 9.51% to $0.12. The company's market cap stands at $1.2 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) shares declined by 7.07% to $0.27. The market value of their outstanding shares is at $11.7 million. </li>
<li>Neuraxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NRXS#AMEX">NRXS</a>) stock fell 6.6% to $2.55. The company's market cap stands at $24.9 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock fell 6.11% to $0.54. The market value of their outstanding shares is at $25.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRNS

CYCC

DHAI

GNLX

HCTI

MEDP

NRXS

ONMD

OVID

TNFA

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Professional Diversity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares moved upwards by 13.9% to $2.9 during Monday's after-market session. The company's market cap stands at $6.0 million. </li>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) shares moved upwards by 9.94% to $0.29. The company's market cap stands at $1.5 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) shares rose 9.61% to $4.9. The company's market cap stands at $155.6 million. </li>
<li>Grab Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) shares rose 9.34% to $5.85. The company's market cap stands at $21.5 billion. </li>
<li>Linkers Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKS#NASDAQ">LNKS</a>) stock rose 7.05% to $0.59. The market value of their outstanding shares is at $7.4 million. </li>
<li>Euro Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLWT#NASDAQ">CLWT</a>) shares rose 6.95% to $1.23. The market value of their outstanding shares is at $9.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lichen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) stock declined by 5.5% to $4.16 during Monday's after-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Roma Green Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROMA#NASDAQ">ROMA</a>) shares declined by 5.24% to $3.35. The company's market cap stands at $52.1 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) stock decreased by 5.14% to $0.47. The market value of their outstanding shares is at $9.1 million. </li>
<li>Safe Pro Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPAI#NASDAQ">SPAI</a>) shares decreased by 5.09% to $3.55. The company's market cap stands at $60.6 million. </li>
<li>WF Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) stock decreased by 4.24% to $1.13. The market value of their outstanding shares is at $28.7 million. </li>
<li>Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) shares fell 4.23% to $11.55. The market value of their outstanding shares is at $380.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLWT

DFLI

GRAB

IPDN

LICN

LNKS

NEOV

ROMA

SPAI

SPIR

ZBAI

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Auddia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) stock moved upwards by 6.5% to $4.39 during Monday's after-market session. The market value of their outstanding shares is at $2.6 million. </li>
<li>CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) shares moved upwards by 6.32% to $3.7. The company's market cap stands at $25.3 million. </li>
<li>Mobilicom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOB#NASDAQ">MOB</a>) shares rose 4.81% to $3.7. The company's market cap stands at $30.4 million. </li>
<li>Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) shares moved upwards by 4.76% to $4.62. The company's market cap stands at $912.0 million. </li>
<li>MMTEC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares increased by 4.52% to $0.92. The company's market cap stands at $22.1 million. </li>
<li>SEALSQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) shares rose 3.79% to $3.56. The market value of their outstanding shares is at $435.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ReAlpha Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) shares declined by 50.9% to $0.42 during Monday's after-market session. The market value of their outstanding shares is at $10.6 million. </li>
<li>Agilysys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) shares declined by 10.22% to $105.0. The market value of their outstanding shares is at $3.2 billion. The company's, Q1 earnings came out today. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares declined by 5.94% to $1.11. The market value of their outstanding shares is at $46.0 million. </li>
<li>Robot Consulting Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAWR#NASDAQ">LAWR</a>) shares decreased by 3.89% to $3.21. The market value of their outstanding shares is at $170.9 million. </li>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) shares declined by 3.68% to $1.31. The market value of their outstanding shares is at $27.0 million. </li>
<li>KVH Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KVHI#NASDAQ">KVHI</a>) shares declined by 3.58% to $5.12. The market value of their outstanding shares is at $104.8 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRE

AUUD

CMBM

INDI

KVHI

LAES

LAWR

MOBX

12 Information Technology Stocks Moving In Monday's After-Market Session

Management

Ashland Names William C. Whitaker Senior Vice President And Chief Financial Officer, Effective July 18, 2025

UYSCR

Trading Halt: Halt status updated at 5:05:00 PM ET: Quotation Resumption: News and Resumption Times

WIIM

AIRE stock has given up its prior loss. ReAlpha Tech shares were trading lower after the company announced a $5 million registered direct offering.

Press Releases

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Health Care

Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Larimar Therapeutics Reports First Quarter 2025 Financial Results

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

Comments

Larimar Therapeutics

Notizie

Ultime notizie per Larimar Therapeutics (NASDAQ:LRMR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO